Long-acting anticholinergic licensed for childhood asthma

Spiriva Respimat (tiotropium) is now licensed for use as add-on maintenance treatment of severe asthma in patients from 6 years.

by Lisa Lytle
The UK has one of the highest prevalence rates for paediatric asthma worldwide, with 1 in 11 children affected. | DAMIEN LOVEGROVE/SCIENCE PHOTO LIBRARY
The UK has one of the highest prevalence rates for paediatric asthma worldwide, with 1 in 11 children affected. | DAMIEN LOVEGROVE/SCIENCE PHOTO LIBRARY

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package